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Abstract
Purpose
To analyze the protein profile of human vitreous of untreated patients with retinal vein occlu-
sion (RVO).
Methods
Sixty-eight vitreous humor (VH) samples (44 from patients with treatment naïve RVO, 24
controls with idiopathic floaters) were analyzed in this clinical-experimental study using cap-
illary electrophoresis coupled to mass spectrometer and tandemmass spectrometry. To
define potential candidate protein markers of RVO, proteomic analysis was performed on
RVO patients (n = 30) and compared with controls (n = 16). To determine validity of potential
biomarker candidates in RVO, receiver operating characteristic (ROC) was performed by
using proteome data of independent RVO (n = 14) and control samples (n = 8).
Results
Ninety-four different proteins (736 tryptic peptides) could be identified. Sixteen proteins
were found to be significant when comparing RVO and control samples (P = 1.43E-05 to
4.48E-02). Five proteins (Clusterin, Complement C3, Ig lambda-like polypeptide 5 (IGLL5),
Opticin and Vitronectin), remained significant after using correction for multiple testing.
These five proteins were also detected significant when comparing subgroups of RVO (cen-
tral RVO, hemi-central RVO, branch RVO) to controls. Using independent samples ROC-
Area under the curve was determined proving the validity of the results: Clusterin 0.884,
Complement C3 0.955, IGLL5 1.000, Opticin 0.741, Vitronectin 0.786. In addition, validation
through ELISA measurements was performed.
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Conclusion
The results of the study reveal that the proteomic composition of VH differed significantly
between the patients with RVO and the controls. The proteins identified may serve as
potential biomarkers for pathogenesis induced by RVO.
Introduction
Retinal vein occlusion (RVO) is the second most common cause of vision loss in older patients
due to retinal vascular disease after diabetic retinopathy [1,2]. Despite major achievements in
diagnosis and treatment perspectives based on spectral OCT, there is still limited understand-
ing of the pathophysiology of RVO [3–6]. A number of cytokines including vascular endothe-
lial growth factor (VEGF) and interleukin-6 (IL-6) have been shown to be associated to RVO.
However these cytokines display high interindividual variations and their concentrations often
do not correspond to the associated clinical RVO phenotype [7,8]. Even in non diseased eyes,
reproducible vitreous protein profiling is quite complicated as the aging vitreous incorporates
different stages of liquefaction and syneresis, which is aggravated after treatment with intravi-
treal injections [9]. Therefore, many aspects of the molecular mechanism of RVO remain
poorly described.
Proteomics is a promising approach allowing the analysis of the total protein content of a
sample and in combination with robust statistical analyses can lead to the identification of pro-
teins associated to specific diseases in ophthalmology [10–13].
In the context of RVO the current proteomic data are incomplete. To the best of our knowl-
edge, only one proteome study in RVO exists. Yao et al. 2013 described the proteome of aque-
ous humor from patients with branch RVO (BRVO; n = 6) compared to controls (n = 6) [14].
Therefore, to potentially improve upon the insight in the pathophysiology of RVO we
performed high-resolution proteome analysis of vitreous humor (VH) of a high number of
patients with RVO (n = 44).
Materials and Methods
Study design
This was a clinical-experimental study. Samples were collected after the approval from local
institutional review board (351/12) of the Goethe University Frankfurt am Main (Germany) in
accordance with the European Guidelines for Good Clinical Practice and the Declaration of
Helsinki. Written informed consent was obtained from each patient before the start of therapy
(linked to the source file of each patient, which was approved by a local ethics committee).
Patient characterization
In our retrospective case series we analyzed a total of 68 undiluted samples from previously
untreated (any intravitreal drug application) patients for VH proteome identification and
quantitative verification; 44 from RVO patients and 24 randomly chosen controls with idio-
pathic floaters. All patients consulted our Department of Ophthalmology between April and
August 2012. Patients suffering neovascular complications such as rubeosis irids, vascularisa-
tions of iridocorneal chamber, neovascularisations of the papilla or in the retina perimeter
were considered ineligible for this study as well as patients with vitreo-macular traction or
patients previously treated with intravitreal anti-VEGF, intraocular steroids, coagulation with
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photo laser, vitrectomy or previous intraocular operations, such as cataract operation at the
included or not included eye in the last six months. Patients with diabetic retinopathy, uveitis,
glaucoma or other compromising ocular conditions were also excluded. For all participants
personal data, such as gender and patient-age, were collected as well as information regarding
type of RVO (central-RVO (CRVO), hemi-central RVO (H-CRVO), BRVO), lens status, aver-
aged and central retinal thickness, posterior attachment of the vitreous body and presence of
retinal cysts with spectral domain OCT (SD-OCT; Topcon 200, Tokyo, Japan).
Tryptic digestion of vitreous
Sampling of VH, sample preparation and analysis was conducted as described in Koss et al.
2014 [12]. In short: 10 μL of the thawed samples were diluted 1:10 with 0.1% SDS, 20 mM
DTT, and 0.1 M Tris-HCl (pH = 7.6). Samples were sonicated at room temperature for 30 min-
utes. Afterwards, the samples were denaturated at 95°C for 3 min and then were incubated for
30 min at room temperature in the absence of light with 0.05 M Iodoacetamide. Eight M urea,
0.2 M Tris-HCl and 50 mM ammonium bicarbonate buffer solution was added and the sam-
ples were applied to NAP-5 columns equilibrated in 50 mM ammonium bicarbonate buffer
solution. Trypsin solution was added to the desalted samples. Trypsin digestion was carried
out overnight at a temperature of 37°C. Subsequently, the samples were lyophilized. Afterwards
the samples were stored at 4°C and were resuspended with 15 μl distilled water shortly before
mass spectrometry analysis.
CE-MS analysis
Capillary electrophoresis coupled to mass spectrometer (CE-MS) analysis was carried out as
described by Theodorescu et al. 2006 [15]. A P/ACE MDQ capillary electrophoresis system
(Beckman Coulter, Brea, CA) being linked online to a micro-TOF MS (Bruker Daltonik, Leip-
zig, Germany) was used. The sprayer (Agilent Technologies, Santa Clara, CA) interfacing the
CE and MS was grounded. 256 nl of the sample was injected hydrodynamically on an untreated
silica capillary (New Objective, Woburn, USA, 90 cm x 50 μm). A solution of 20% acetonitrile
(Sigma-Aldrich, Taufkirchen, Germany) in HPLC-grade water (Roth, Karlsruhe, Germany)
supplemented with 0.94% formic acid (Sigma-Aldrich) was used as running buffer. Interface
potential was adjusted to -4.5 kV. The capillary temperature was held at 35°C. Mass spectra
were recorded for three seconds with signals at an m/z range between 350 and 3000. The detec-
tion limit of the TOF-Analyzer was 1 fmol [15].
Data processing of CE-MS analysis
Analysis of raw CE-MS data was carried out via MosaiquesVisu version 2.1.0 (mosaigues diag-
nostics GmbH, Hannover, Germany) which uses isotope identification and conjugated mass
detection for mass deconvolution [16]. Only signals observed in a minimum of 3 consecutive
spectra with a signal-to-noise (SNR) ratio of at least 4 were considered. The observed minimal
signal intensity with SNR>4 was 1.2. The software automatically eliminates all signals that
can be detected only as singly charged species. The software employs a probabilistic clustering
algorithm and uses both, isotopic distribution and conjugated masses for charge-state determi-
nation of peptides/proteins. The resulting peak list characterizes each polypeptide by its molec-
ular mass, CE-migration time, and ion signal intensity (amplitude) value. Mass spectral ion
peaks from the same molecule at different charge states were deconvoluted and summarized
into a single mass. To minimize effects of biological and analytical variability between the dif-
ferent lots, a normalization of retention time, signal intensity and mass was performed. In
total, 292 signals for mass and CE-time with a frequency35% could be determined that
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served as reference signals for normalization of peptide CE-time using local regression. The
detected signal intensities for each individual peptide were normalized to the total ion count
(total intensity) per individual sample analysis (ppm normalization).
All normalized peptides were deposited, matched, and annotated in a Microsoft SQL data-
base, allowing further analysis and comparison of multiple samples [17]. Peptides were consid-
ered identical when deviation of mass was<±50 ppm (parts per million) for an 800 Da protein
fragment, respectively<±75 ppm for a 15 kDa protein fragment. Peptides were considered
identical if the CE-migration time window did not exceed 2–5%, continuously increasing
between 10 and 60 min.
Peptide sequencing
Nine lyophilized, tryptic-digested randomly selected vitreous samples were dissolved in 15 μL
distilled water for MS/MS analysis. Separation was carried out via Dionex Ultimate 3000 RSLS
nano flow system (Dionex, Camberly UK) as described by Metzger et al. [18]. After loading
5 μl onto a Dionex 0.1×20 mm 5 μm C18 nano trap column at a flowrate of 5 μl/min in 98%
0.1% formic acid and 2% acetonitrile, sample was eluted onto an Acclaim PepMap C18 nano
column 75 μm×15 cm, 2 μm 100 Å at a flow rate of 0.3 μl/min. The trap and nano flow column
were maintained at 35°C. The samples were eluted with a gradient of solvent A: 98% 0.1% for-
mic acid, 2% acetonitrile versus solvent B: 80% acetonitrile, 20% 0.1% formic acid starting at
1% B for 5 minutes rising to 20% B after 90 min and finally to 40% B after 120 min. Subse-
quently, the column was washed and re-equilibrated prior to the next injection. The Proxeon
nano spray ESI source (Thermo Fisher Hemel UK) in positive ion mode was used for samples
ionisation. Ionization voltage was 2.6 kV, the capillary temperature was 200°C. The samples
were analysed using an LTQ Orbitrap Velos (Thermo Finnigan, Bremen, Germany). The
mass spectrometer was operated in MS/MS mode scanning from 380 to 2000 amu. The sam-
ples were analysed using both CID and HCD to obtain the maximum number of sequence
identifications. The top 20 multiply charged ions were selected from each scan for MS/MS
analysis using either CID or HCD at 40% collision energy. The resolution of ions in MS1 was
60,000 and 7,500 for mass fragmentation MS2. The searches were performed by the use of
Proteome Discoverer (version 1.3, Thermo Fisher Scientific, Bremen, Germany) with the use
of the SEQUEST algorithm and against the human, non redundant IPI database (version 3.87,
entry count: 91464) for each data file separately. Trypsin was used as the enzyme while screen-
ing for proteins. Hydroxylated proline from collagen fragments and oxidation of methionine
were accepted as variable modifications and carbamidomethylated cysteine as fixed modifica-
tion. A maximal mass deviation of 10 ppm for precursor ions and 0.8 Da for product ions was
accepted. The allowed false discovery rate was 1% and the number missed cuts one. In addi-
tion, only peptides with medium or high confidence, rank one and XCorr factor>0.8 were
accepted.
The sequences were matched to the detected CE-MS data according to Zürbig et al. [19].
Charge of the peptides was used in this matching procedure instead of the LC retention time.
On the basis of their charge, discrimination between peptides with similar masses can be per-
formed even when having identical or very close masses in the liquid chromatography coupled
with tandem mass spectrometry (LC-MS/MS) analysis. This is due to the fact that the number
of basic and neutral polar amino acids of peptide sequences distinctly correlates with their
CE-MS migration time/molecular weight coordinates. This enables linking a unique LC-MS/
MS peptide to a CE-MS peptide in nearly all cases [19]. This procedure has been successfully
used in a number of studies linking specific CE-MS-identified peptides to sequences obtained
by LC-MS/MS [12,18,20–22].
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CE-MS peptides with sequencing information were combined for each protein. Proteins
were accepted when being represented by a minimum of two peptides. Protein abundance was
calculated as the average of all normalized CE-MS peptide intensities for the given protein.
ELISA
Clusterin, Complement C3, Ig lambda-like polypeptide 5 (IGLL5), Opticin and Vitronectin
concentrations were assayed in sandwich-ELISAs (Cloud-Clone Corporation, Houston, TX,
USA) where antibodies specific to the target proteins were precoated to a microtiterplate. After
antigen binding to the precoated plates biotin-conjugated antibodies specific for Clusterin,
Complement C3, Opticin or Vitronectin were used for detection of the bound antigens. Horse-
radish peroxidase conjugated to avidine and TMB substrate were applied for quantification.
Measurements were conducted spectrophotometrically at 450nm. Minimum detectable doses
were 3 ng/ml for Clusterin, 2 ng/ml for Complement C3, 0,2 ng/ml for IGLL5, 0,1 ng/ml for
Opticin, and 0,5 pg/ml for Vitronectin.
Statistical methods
SPSS version 21.0 was used for statistical analysis. A P-value of α<5.00E-02 was considered sta-
tistically significant.
Descriptive Statistics. For the descriptive data analysis, mean ± standard deviation (SD),
median values, and minimal and maximal values were calculated.
Patient Characterization. Clinical and demographic characteristics of control patients
and each subgroup of RVO (CRVO, H-CRVO, BRVO) was compared by using the Kruskal
Wallis test where appropriate.
Proteomic Analysis. Candidate RVO biomarkers were defined by examination of differ-
ences in signal intensity of the proteins between the RVO-patients and the controls. Mean
CE-MS based protein signal intensity was used as a measure for relative abundance. Mann-
Whitney test was used for analysis. Multiple hypotheses testing correction was performed by
using the Benjamini-Hochberg test for false discovery rate [23].
Subgroup Analysis. Patients with RVO were subdivided in following subgroups: CRVO,
H-CRVO, BRVO. The closed testing procedure was used for subgroup analysis [24]. For
detailed information see Fig 1.
Influence of past time period since suffering RVO on biomarker discovery. To analyze
the influence of past time period since suffering RVO we compared protein signal intensity
between fresh (patients suffered RVO<8 weeks ago) and old RVO-samples (patients suffered
RVO8 weeks ago) versus controls. The Mann-Whitney test was used for analysis.
Validation of Selected Potential Biomarker Candidates. To determine validity of poten-
tial biomarker candidates in RVO, receiver operating characteristic (ROC) was performed by
using data of randomly selected, independent control and RVO samples not being used in
proteomic analysis and biomarker definitions. Area under the curve (AUC) was determined.
Furthermore, the protein abundance in VH of the selected potential biomarkers was measured
by ELISA. Mann-Whitney test was used to analyze changes in the protein abundance between
RVO and controls in the ELISA.
Results
Patient characterization
A total of 44 RVO samples and 24 controls with idiopathic floaters were analyzed. Patients
with RVO were additionally subdivided in the following subgroups: CRVO (n = 20), H-CRVO
Proteomics in Retinal Vein Occlusion
PLOS ONE | DOI:10.1371/journal.pone.0158001 June 30, 2016 5 / 19
(n = 9), BRVO (n = 15). Epidemiologic data and further patient information such as fresh/old
RVO, lens status, retinal thickness, attachment of the vitreous body, and presence of retinal
cysts are listed in Table 1 (for detailed information see S1 Table). No differences between sub-
groups regarding patient-age and average or center retinal thickness were observed (P = 1.60E-
01 to 5.48E-01).
Proteomic analysis
The study layout is depicted in Fig 1. Samples were randomly subdivided for selection and veri-
fication of potential biomarker candidates. Two thirds of all samples were used as a discovery
set and selection of potential biomarker candidates and subgroup analysis (16 controls, 14
CRVO, 6 H-CRVO, 10 BRVO); one third was used for the validation using ROC analysis (8
controls, 6 CRVO, 3 H-CRVO, 5 BRVO). The two mass spectrometry techniques employed in
Fig 1. Study layout.
doi:10.1371/journal.pone.0158001.g001
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this study are used in a complementary fashion. CE-MS, due to its high reproducibility, is used
for candidate peptide selection while LC-MS/MS is used for identification of the biomarker
peptides. Using LC-MS/MS analysis, 736 of the tryptic peptides detected with CE-MS could be
sequenced. The mass of sequenced peptides ranged between 800.4 and 3619.0 Da. Migration
time ranged between 20.1 and 38.0 min. The 736 tryptic peptides corresponded to 94 different
proteins in VH (S2 Table, Fig 1). For detailed information regarding all raw data see S3 Table.
In the interest of greater clarity, we deleted keratins (8 proteins, 72 peptides) and dermcidin (2
peptides) from the list since these proteins are only artifacts and aren’t proteins of vitreous
humor. For all raw data see ftp://PASS00883:PZ4442mcv@ftp.peptideatlas.org.
Selection of potential biomarker candidates
In the discovery study, the comparison of protein data between RVO (irrespective of subgroup)
and control samples resulted in 16 significant proteins (P = 1.43E-05 to 4.48E-02; Table 2).
After using correction for multiple testing, five proteins remained significant (Table 2, see ;
Fig 1): Clusterin, Complement C3, IGLL5, Opticin and Vitronectin.
Subgroup analysis
Signal intensity of the proteins of each subgroup (CRVO, H-CRVO, BRVO) and the controls
was compared by using the closed testing procedure (see S1 Fig). Proteins being detected signif-
icantly different in any of the analysis are listed in Table 3. In step 3 ten proteins were expressed
significantly different in each, CRVO and BRVO samples versus controls, 9 proteins were
expressed significantly different in H-CRVO versus controls. Five proteins remained signifi-
cant in all comparisons of step 1 to step 3: Clusterin, Complement C3, IGLL5, Opticin and
Vitronectin. For detailed information regarding subgroup analysis see S4 Table.
Influence of past time period since suffering RVO on biomarker
discovery
When analyzing the influence of past time period since suffering RVO Clusterin, Ig lambda-
like polypeptide 5 (IGLL5), Opticin and Vitronectin remained significantly different between
control samples (n = 16) versus fresh (n = 22) or old RVO-samples (n = 8) (S5 Table). Except
for Apolipoprotein A-II (P = 1.75E-02) no difference was detected of the potential biomarkers
Table 1. Epidemiology.
CRVO Hemi-CRVO BRVO Control
N 20 9 15 24
Fresh/Old 14/6 7/2 11/4 -
Female/Male 8/12 4/5 10/5 13/11
Age in years (mean ± SD) 67.6 ± 14.3* 69.2 ± 14.2* 68.4 ± 12.2* 62.7 ± 11.7*
Phakic/Pseudophakic 16/4 8/1 13/2 12/12
Average Thickness in μm (mean ± SD) 376.3 ± 82.8* 351.33 ± 44.2* 351.5 ± 69.6* -
Center Thickness in μm (mean ± SD) 513.8 ± 196.9* 443.4 ± 142.2* 462.0 ± 149.9* -
Posterior Vitreous attached/ detached/unrecognizable 6/14/0 3/5/1 0/14/1 -
Cysts yes/no 15/5 8/1 13/2 -
* Kruskal Wallis test was used for analyses; P-Value of α<5.00E-02 was considered significant. No significant difference was tested: Age P = 3.71E-01;
Average Thickness P = 1.60E-01; Center Thickness P = 5.48E-01
doi:10.1371/journal.pone.0158001.t001
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Table 2. Significant proteins in vitreous humor. Significant proteins were detected by capillary electrophoresis coupled to mass spectrometer (CE-MS)
and identified by tandemmass spectrometry (LC-MS/MS) when comparing protein signal intensity of retinal vein occlusion (RVO)-samples compared to con-
trol-samples.
Protein UniProt‡ RVO (n = 30) Control (n = 16) P-
Value§
Benjamini-
Hochberg
(adjusted
P-Value)
Protein
identification
Statistical analysis Protein
identification
Statistical analysis
Pep-
tides##
Cover-
age†
N# Mean
intensity
SD Pep-
tides##
Cover-
age†
N# Mean
intensity
SD
Upregulation Ig lambda-like
polypeptide 5*
B9A064 3 20 30 358.2 422.5 2 13 11 93.4 75.7 1.43E-
05
1.37E-03
Vitronectin* P04004 4 10 25 89.6 136.0 3 8 8 8.8 11.0 2.74E-
04
8.77E-03
Clusterin* P10909 9 26 30 524.1 194.2 10 28 15 282.3 174.6 4.97E-
04
1.19E-02
Complement
C3*
P01024 43 29 30 582.3 134.3 41 27 16 390.2 194.5 1.85E-
03
3.55E-02
Collagen
alpha-2(XI)
chain
P13942 3 6 30 740.4 678.7 5 9 13 377.1 528.5 8.55E-
03
1.10E-01
Collagen
alpha-1(VII)
chain
Q02388 3 2 5 29.3 101.6 2 1 8 25.1 57.2 2.94E-
02
1.88E-01
Collagen
alpha-2(I) chain
P08123 4 7 18 15.1 15.8 4 7 6 5.1 8.1 4.32E-
02
2.53E-01
Collagen
alpha-1(III)
chain
P02461 3 4 23 93.4 91.6 3 4 10 37.9 41.8 4.48E-
02
2.53E-01
Downregulation Opticin* Q9UBM4 6 20 23 82.8 207.2 5 16 16 163.7 95.1 7.07E-
05
3.39E-03
Neuroblast
differentiation
associated
protein AHNAK
Q09666 2 1 6 1.4 3.9 4 1 9 14.0 24.8 3.34E-
03
5.34E-02
Alpha-crystallin
B chain
P02511 2 11 3 1.9 7.4 5 30 7 30.1 75.5 9.20E-
03
1.10E-01
Complement
factor B
P00751 2 3 13 18.1 60.4 4 6 11 44.9 61.4 1.23E-
02
1.31E-01
Obscurin Q5VST9 2 <1 21 520.3 1358.1 2 <1 16 1767.1 3857.7 1.51E-
02
1.31E-01
Apolipoprotein
A-II
P02652 2 29 10 8.1 14.4 4 41 10 50.1 67.6 1.78E-
02
1.41E-01
Complement
C4-A
P0C0L4 2 2 4 2.0 6.9 4 3 7 29.3 78.3 1.91E-
02
1.41E-01
Serum albumin P02768 40 61 30 2109.7 657.6 42 65 16 2910.3 1163.1 2.11E-
02
1.45E-01
‡ Listed in the universal protein resource (UniProt), a central repository of protein data.
## Number of peptides observed by CE-MS analysis and sequenced by LC-MS/MS for each protein.
† Percentage (%) of peptide coverage of the protein sequence.
# Number of samples with a signal intensity >0
§ P-Value was analyzed by using the Mann-Whitney test. A P of α<5.00E-02 was considered statistically significant.
* Proteins which remained significant after performing multiple hypotheses testing correction, analyzed by using the Benjamini-Hochberg test for false
discovery rate. An adjusted P-Value of α<5.00E-02 was considered statistically significant.
doi:10.1371/journal.pone.0158001.t002
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when comparing signal intensity of the proteins between the fresh versus old RVO-samples
(P = 8.27E-02 to 9.68E-01; S5 Table).
Verification of selected potential biomarker candidates
Fig 2 shows the comparison of signal intensity of Clusterin, Complement C3, IGLL5, Opticin
and Vitronectin in the control group (n = 16) compared to the three subgroups in the discovery
cohort (14 CRVO, 6 H-CRVO, 10 BRVO) and compared to the total discovery cohort (30
RVO). All these proteins remained significant after using correction for multiple testing when
comparing RVO versus controls (Table 2) and were listed significant in each comparison of
the subgroup analysis (Table 3). Therefore, these proteins were considered for verification of
potential biomarker candidates (Fig 1).
To determine validity of potential biomarker candidates in RVO, we performed receiver
operating characteristic (ROC) analysis (Fig 3) using randomly selected, independent samples.
For analyses we used data of 8 controls and 14 RVO patients that were not included in analyses
of biomarker definitions. AUCs were: Clusterin 0.884 (P = 3.34E-03), Complement C3 0.955
(P = 5.00E-04), IGLL5 1.000 (P = 1.32E-04), Opticin 0.741 (P = 6.54E-02), Vitronectin 0.786
(P = 2.90E-02). Fig 4 shows the comparison of signal intensity of the 5 proteins in the control
group (n = 8) compared to the three subgroups in the discovery cohort (6 CRVO, 3 H-CRVO,
5 BRVO) and compared to the total discovery cohort (14 RVO).
The vitreal protein concentration of Clusterin, Complement C3, IGLL5, Opticin and Vitro-
nectin was also measured using ELISA. Twelve RVO and twelve control samples were used.
All Clusterin, Complement C3, Opticin and Vitronectin analyzed proteins were successfully
detected in all vitreous samples. Unfortunately, we were not able to detect IGLL5 in any of the
vitreous samples. Opticin displayed reduced abundance, whereas Clusterin, Complement C3
and Vitronectin showed increased abundance in the VH in the RVO group (see Table 4). Thus,
the variations in the protein concentration observed by ELISA corresponded to the changes in
signal intensity identified by mass spectrometry analysis. All four detected proteins showed a
significant difference in the protein abundance between the RVO and the control group (see
Table 4). Thus, the ELISA results further affirm our primary findings by mass spectrometry.
Discussion
The aim of this study was to analyze the protein profile of undiluted human vitreous of
untreated patients with RVO and to identify potential biomarkers that are associated with the
pathophysiology of the disease. CE-MS and LC-MS/MS were used for sample analysis in this
study. CE-MS is a powerful and very reproducible technology platform with known perfor-
mance characteristics [25] and therefore is used as one of the most advanced techniques for the
discovery of new protein biomarkers of clinical significance [25–28]. Furthermore, CE-MS
allows the characterization of highly complex samples in a consistent and reproducible way
and has a high reproducibility allowing the comparison of the protein content of samples over
time [25,29]. LC-MS/MS was used in this study to provide sequence information (i.e. identify)
of the CE-MS detected peptides.
Potential biomarker candidates
Comparing the proteome of 30 RVO patients and 16 controls, we could define 16 proteins
that were significantly up- or downregulated in RVO. Thrombosis and thrombolysis are
involved in RVO as well as inflammatory processes due to hypoxic induced cell death [30].
This could be confirmed in our study as inflammatory response pathway, complement activa-
tion (classical pathway) as well as complement and coagulation cascades were identified as
Proteomics in Retinal Vein Occlusion
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Fig 2. Comparison of signal intensity of potential biomarker proteins.Comparison of signal intensity of proteins remained significant after
using correction for multiple testing (Benjamini-Hochberg test) when comparing retinal vein occlusion (RVO) versus controls (see *; Table 2) of
samples used for biomarker candidates identification (discovery set). Mann-Whitney test was used for analysis. A P of α<5.00E-02 was
considered statistically significant. RVO was subdivided in following subgroups: Central-RVO (CRVO), hemi-central RVO (H-CRVO), branch
RVO (BRVO).
doi:10.1371/journal.pone.0158001.g002
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Fig 3. Biomarker validation—Receiver operating characteristic (ROC) curves of selected candidate
proteins. Independent samples of 14 patients suffered a retinal vein occlusion (RVO) and 8 controls were
used. The area under the curve (AUC) was shown for RVO at 95% confidence level (95% CI).
doi:10.1371/journal.pone.0158001.g003
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Fig 4. Comparison of signal intensity of proteins used for biomarker validation.Mann-Whitney test was used for analysis. A P of
α<5.00E-02 was considered statistically significant. Significant values are written in bold. Retinal vein occlusion (RVO) was subdivided in
following subgroups: Central-RVO (CRVO), hemi-central RVO (H-CRVO), branch RVO (BRVO).
doi:10.1371/journal.pone.0158001.g004
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PLOS ONE | DOI:10.1371/journal.pone.0158001 June 30, 2016 13 / 19
primary pathways of the 16 significant up- or downregulated proteins in VH of RVO patients
compared to controls.
We believe, that five of the 16 significant proteins, Clusterin, Complement C3, IGLL5, Opti-
cin and Vitronectin, are of special interest as they remained significant after multiple testing,
analysis of fresh versus old RVO, and subgroup analysis (CRVO, H-CRVO, BRVO versus
controls).
Clusterin is a glycoprotein with a nearly ubiquitous tissue distribution and an apparent
involvement in a number of biological processes, including inter alia lipid transport, mem-
brane recycling, cell adhesion, programmed cell death, and complement cascade [31,32]. Inter-
estingly, increased blood levels of Clusterin are associated with atrophy of the entorhinal cortex
in Alzheimer’s disease for which this protein seems to be a marker of disease severity [33].
Therefore, upregulated Clusterin levels may indicate biochemical signs of a neurodegenerative
disease. Our findings indicate for the first time that Clusterin in VH is associated with retinal
disease like RVO.
Complement C3 plays a central role in the activation of complement system. Among other
things, it is involved in the adaptive immune response to select the appropriate antigens for a
humoral response, promotes phagocytosis and supports local inflammatory responses against
pathogens [34]. Complement C3 might thus be involved in the well known phagocytic and
inflammatory process subsequent to the onset of RVO.
Similar to Complement C3, IGLL5 demonstrated upregulation in RVO. IGLL5 could also
be involved in immune processes being associated with cell death due to RVO although IGLL5
seems not to be expressed in pre-B-cells (http://uniprot.org). In general little is known about
IGLL5 in the literature and further research is needed to explain the association of high IGLL5
levels in VH of patients with RVO.
Opticin is a protein produced by the non-pigmented ciliary epithelium. It is present in sig-
nificant quantities in the vitreous of the eye and also localizes at the cornea, the iris, the ciliary
body, the optic nerve, the choroid and the retina. It can noncovalently bind collagen fibrils
and regulate fibril morphology, spacing, and organization [35]. Furthermore, Opticin was
found to be located, besides various ocular tissues, especially in basal and cortical vitreous and
adjacent basement membranes, like the internal limiting membrane, suggesting a possible role
in vitreoretinal adhesion [36]. Therefore, decreased Opticin levels may be correlated with mac-
ula edema due to RVO.
Vitronectin is an abundant glycoprotein which promotes cell adhesion and spreading, inhib-
its the membrane damaging effect of the terminal cytolytic complement pathway, and binds to
Table 4. Biomarker validation—Enzyme Linked Immunosorbent Assay (ELISA). Vitreal levels of our five potential biomarkers in retinal vein occlusion
(RVO, n = 12) and control samples (n = 12) messured by ELISA.
Protein UniProt‡ RVO (n = 12) Control (n = 12) P-Value§ RVO vs.
ControlN# Mean SD Min Max N# Mean SD Min Max
Clusterin (ng/ml) P10909 12 16.7 2.4 12.7 19.9 12 6.6 2.0 3.2 9.9 3.12E-05
Complement C3 (ng/ml) P01024 12 3659.6 336.0 3188.0 4111.0 12 3241.3 464.3 2268.4 3657.8 3.77E-02
Immunoglobulin lambda-like
polypeptide
B9A064 0 - - - - 0 - - - - -
Opticin (pg/ml) Q9UBM 12 524.3 83.6 412.0 632.0 12 579.7 90.2 450 734 4.94E-02
Vitronectin (ng/ml) P04004 12 74.3 21.7 51.8 117.0 12 26.2 17.7 8.1 55.7 1.36E-04
‡ Listed in the universal protein resource (UniProt), a central repository of protein data.
# Number of samples in which the proteins were detected with ELISA
§ P-Value was analyzed by using the Mann-Whitney test. A P of α<5.00E-02 was considered statistically significant
doi:10.1371/journal.pone.0158001.t004
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several serpins. By its localization in the extracellular matrix and its binding to plasminogen
activation inhibitor-1, vitronectin can potentially regulate the proteolytic degradation of this
matrix. In addition, vitronectin binds to complement, to heparin and to thrombin-antithrombin
III complexes, showing its participation in the immune response and in the regulation of clot
formation [37]. Therefore, upregulation of Vitronectin in RVO potentially plays a role in the
disease.
Advantages and limitations of the study
To our knowledge, this is the first proteomics study using a high number (n = 30 and 16 idio-
pathic vitreous floaters as controls) of undiluted VH of RVO patients and validation of the 5
most significant proteins in an independent data set of an additional 8 controls and 14 RVO
patients. We could only confirm 3 of the proteins 36 different proteins of the Yao et al. study
[14] (Alpha-crystallin B chain, Beta-crystallin B2, Serum albumin) mostly due to this difference
in power and the fact that they used 2-dimensional electrophoresis coupled with MS providing
a different coverage of the proteome. Furthermore, we compared our results with other high
throughput studies on VH. We have identified 85 proteins by other studies of vitreous humor
proteome [12,38–40]. In addition, we have identified 9 novel VH proteins (see S2 Table) not
described in previous studies, although our study fails to detect more than 94 proteins com-
pared to the studies of Aretz et al. and Murthy et al. which detected in total 1111, respectively
1205 proteins in VH.
Nevertheless, there are some limitations of our study. First of all, there might be some bias
in biomarker definitions by using patients with idiopathic vitreous floaters as controls. The
existence of idiopathic vitreous floaters might have an influence on protein profile in vitreous
body and therefore might have an influence of biomarker definitions in this study. Further-
more, highly abundant VH proteins such as albumin and immunoglobulin were not depleted
in this study, possibly preventing the detection of less abundant proteins [41]. This seems to be
the reason why only 94 proteins were identified although one would expect a higher number of
proteins in human VH and why the number of detected peptides and coverage is low for some
proteins (see S2 Table and Table 2), limiting statistical analysis of these proteins. In addition,
depletion of highly abundant proteins does not necessarily lead to increased detection of low
abundance proteins. On the contrary it has been shown that depletion can lead to co-depletion
of many other proteins as shown for the analysis of the plasma proteome [42]. Another limita-
tion of our study is the high variability of the mean intensity in some identified proteins result-
ing in a high SD (see for example Tables 2 and 3). The high variability may be induced by
accepting identification of proteins when being represented by only two peptides. In future
studies variability of the mean intensity of the proteins could be reduced by accepting identifi-
cation of proteins when being represented in more than two peptides or by higher group sizes,
leading to the next limitation of our study, the limited subgroup sizes. Although performing
proteomic analysis of in total 68 participants (Proteomic analysis: 30 RVO, 16 controls; ROC
analysis: 14 RVO, 8 controls) bigger group sizes would be desirable to further improve the
power. Furthermore, with bigger group sizes one would expect significant results in all analyses
of verification of potential biomarker candidates.
Conclusions
In this retrospective, clinical-experimental study we applied a reproducible proteomics detec-
tion method in a high number of undiluted vitreous humor of patients with RVO. Our findings
were thoroughly statistically evaluated and yielded five potential biomarker candidates associ-
ated with the pathophysiology of RVO: Clusterin, Complement C3, IGLL5, Opticin and
Proteomics in Retinal Vein Occlusion
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Vitronectin. Future studies are needed to validate our substantial findings, which might be
helpful regarding future diagnostic or therapeutic approaches in RVO. These studies should
deplete highly abundant VH proteins such as albumin and immunoglobulin to determine
more precisely potential biomarker candidates associated with the pathophysiology of RVO.
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